Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Benjamin O. Anderson MD, FACS Advisory Board

Alexander C. J. van Akkooi MD, PhD, FRACS Associate Editor

Jeffrey J. Kirshner MD, FACP, FASCO Advisory Board

See All Experts

Published in Oncology

Journal Scan / Research · August 24, 2022

Risk and Incidence of Head and Neck Cancers in Veterans Living With HIV

Cancer

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Charles Gaulin MBBS

Cancer

Risk and incidence of head and neck cancers in veterans living with HIV and matched HIV-negative veterans

Cancer 2022 Jul 22;[EPub Ahead of Print], AL Mazul, CM Hartman, YM Mowery, JR Kramer, DL White, KE Royse, S Raychaudhury, VC Sandulache, ST Ahmed, JP Zevallos, PA Richardson, AG Sikora, EY Chiao

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Risk and Incidence of Head and Neck Cancers in Veterans Living With HIV

Additional Info

Risk and incidence of head and neck cancers in veterans living with HIV and matched HIV-negative veterans

Further Reading

ASH 2024: Abstract Recommendations From Drs. Evani Patel and David Henry

ASH 2024: Abstract Recommendations From Dr. Rafael Fonseca

An Integrative Precision Medicine Approach Using Genomics and Avatar Models to Guide Treatment in Pancreatic Cancer

Disease-Free Survival as a Surrogate for Overall Survival in Esophageal Cancer in Real-World Settings

Long-Term Outcomes After Adding a Contact X-Ray Brachytherapy Boost to Standard Neoadjuvant Chemoradiotherapy for Organ Preservation in Patients With Early Rectal Adenocarcinoma

Comparison of First-Line Chemotherapy Regimens in Unresectable Locally Advanced or Metastatic Pancreatic Cancer

Safety and Efficacy of Pembrolizumab, Radiation Therapy, and Surgery in Patients With Stage III Soft Tissue Sarcoma of the Extremity

Glutaminase Inhibition Plus Azacitidine for Myelodysplastic Syndromes

The Lancet Breast Cancer Commission: Evidence-Based Roadmap to Address Urgent Global Breast Cancer Challenges

Next-Generation Oral SERD Camizestrant vs Fulvestrant in Postmenopausal ER+/HER2− Advanced Breast Cancer

Zanubrutinib, Obinutuzumab, and Venetoclax as a First-Line Treatment for TP53-Mutant Mantle Cell Lymphoma

Recently Updated